Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 2;11:981. doi: 10.3389/fneur.2020.00981

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Mantegazza and Antozzi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Innovative therapies in Myasthenia Gravis and their site of action. A schematic drawing of autoreactive B cells, T cells and Plasmablasts/Plasmacells leading to the production of autoreactive antibodies. The site of action of the new therapies, indicated in black boxes, is also indicated. BAFF, B cell activating factor; CD20, B-lymphocyte antigen CD20; CFZ533, monoclonal antibody to CD40; Th1, T helper cell type 1; Treg, regulatory T cell; P, Proteasome; AChR, Acetylcholine Receptor; MuSK, Muscle Specific Kinase; LRP4, low density lipoprotein receptor-related protein 4; nFcR, immunoglobulin neonatal Fc Receptor; C5, complement component C5; C5a and b, fragments of C5.